HC Wainwright Reaffirms Buy Rating for Phathom Pharmaceuticals (NASDAQ:PHAT)
Phathom Pharmaceuticals (NASDAQ:PHAT – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $20.00 target price on the stock. HC Wainwright’s price objective would suggest a potential upside of 122.97% from the […]
Phathom Pharmaceuticals (NASDAQ:PHAT – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $20.00 target price on the stock. HC Wainwright’s price objective would suggest a potential upside of 122.97% from the […]
